Numbers and percentages of subjects reporting immunosuppressant therapy according to time since HCT and cGVHD status
Time since transplantation . | No cGVHD, no. (%) . | . | P, none vs resolved . | Resolved cGVHD, no. (%) . | . | P, none vs active . | Active cGVHD, no. (%) . | . | P, resolved vs active . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Yes . | No . | . | Yes . | No . | . | Yes . | No . | . | |||
| 2-5 y | 24 (30.8) | 54 (69.2) | .49 | 19 (36.5) | 33 (63.5) | < .001 | 70 (88.6) | 9 (11.4) | < .001 | |||
| 6-10 y | 4 (5.8) | 65 (94.2) | .07 | 9 (15.5) | 49 (84.5) | < .001 | 34 (81.0) | 8 (19.0) | < .001 | |||
| 11-28 y | 6 (4.8) | 118 (95.2) | .30 | 1 (1.7) | 58 (98.3) | < .001 | 9 (39.1) | 14 (60.9) | < .001 | |||
Time since transplantation . | No cGVHD, no. (%) . | . | P, none vs resolved . | Resolved cGVHD, no. (%) . | . | P, none vs active . | Active cGVHD, no. (%) . | . | P, resolved vs active . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | Yes . | No . | . | Yes . | No . | . | Yes . | No . | . | |||
| 2-5 y | 24 (30.8) | 54 (69.2) | .49 | 19 (36.5) | 33 (63.5) | < .001 | 70 (88.6) | 9 (11.4) | < .001 | |||
| 6-10 y | 4 (5.8) | 65 (94.2) | .07 | 9 (15.5) | 49 (84.5) | < .001 | 34 (81.0) | 8 (19.0) | < .001 | |||
| 11-28 y | 6 (4.8) | 118 (95.2) | .30 | 1 (1.7) | 58 (98.3) | < .001 | 9 (39.1) | 14 (60.9) | < .001 | |||
For no cGVHD, n = 271; for resolved cGVHD, n = 160; and for active cGVHD, n = 144